-
Catalpol, Glycolysis, and Src Signaling in Liver Fibrosis
2026-09-03
A 2024 Phytomedicine study shows that catalpol suppresses hepatic fibrosis by reducing aerobic glycolysis in activated hepatic stellate cells through an EphA2/FAK/Src signaling axis. Its combination of animal, cellular, target-engagement, and pathway-intervention experiments provides a mechanistic framework for evaluating metabolism-linked antifibrotic strategies.
-
Podophyllotoxin Workflows for Cancer Cell Studies
2026-09-02
Build a reproducible Podophyllotoxin workflow around microtubule disruption, cell-cycle profiling, apoptosis, and autophagy-flux measurements. A recent hepatocellular carcinoma study adds a valuable comparison point by showing why growth inhibition and protective autophagy must be interpreted with orthogonal assays.
-
Bifendate (DDB): From Autophagy Flux to Assay Design
2026-09-02
Bifendate (DDB) is more than a hepatoprotection agent: its effects on autophagy flux, lysosomal function, and lipid droplets create a framework for better liver disease assays. This guide translates mechanistic evidence into practical experimental decisions.
-
CD38 CAR Binder Structures and Affinity Tuning
2026-09-01
The reference study resolves how two CD38-targeting CAR binders, RP02 and 028, use different epitopes and structural mechanisms to influence antigen recognition, enzymatic inhibition, and CAR-T selectivity. Its affinity-attenuated 028R103G design reduced fratricide while preserving cytotoxicity, illustrating how structural information can guide safer CD38-directed cell therapies.
-
Entecavir in Decompensated Chronic Hepatitis B
2026-09-01
Keating’s 2011 review integrates pharmacology, pharmacokinetics, comparative clinical evidence, and tolerability data for Entecavir in chronic hepatitis B with decompensated liver disease. Its principal contribution is a clinically focused interpretation of potent HBV suppression and a high resistance barrier in a population where antiviral choice, renal function, and hepatic reserve strongly influence outcomes.
-
DDI2–NFE2L1 Protects Cells from Ferroptosis
2026-08-31
The reference study identifies DDI2-mediated activation of NFE2L1 as an adaptive mechanism that restores proteasome function during ferroptotic stress. Its combination of ubiquitin-site proteomics, genetic perturbation, and chemical inhibition shows how disrupting this pathway increases ferroptosis sensitivity and suggests a framework for studying proteostasis-dependent cancer vulnerabilities.
-
Mildronate Lipidoids for Safer mRNA Vaccine Delivery
2026-08-31
A 2024 ACS Nano study developed mildronate-derived cationic lipidoids for low-dose lipid nanoparticles that maintained effective mRNA delivery while reducing local inflammation compared with an SM102-based formulation. In prophylactic and therapeutic B16OVA melanoma models, the mLNP-69 system supported antitumor mRNA vaccination, providing a preclinical framework for balancing transfection efficiency with tolerability.
-
RG108 for Reliable Cell Viability Assays
2026-08-30
Learn how RG108 (SKU A1913) can improve the interpretation and reproducibility of cell viability, proliferation, and cytotoxicity workflows involving DNA methylation. This scenario-based guide covers mechanism, solvent compatibility, dose–time optimization, data interpretation, and practical product selection.
-
Merimepodib (VX-497): A Metabolic Antiviral Lens
2026-08-29
Merimepodib (VX-497) is an IMPDH inhibitor that reveals how guanine nucleotide metabolism shapes lymphocyte function and viral replication. This article focuses on assay interpretation, host-dependency mapping, and practical experimental design using evidence from PEDV research.
-
FPH1 (BRD-6125): Function-First Liver Models
2026-08-28
FPH1 (BRD-6125) supports a function-first strategy for expanding and evaluating human hepatocytes. This article connects proliferation, hepatic maturity, assay design, and the emerging value of controllable gene-expression systems without overstating current evidence.
-
AS1842856 Foxo1 Inhibitor for Metabolic Assays
2026-08-28
AS1842856 enables activity-focused interrogation of Foxo1 in gluconeogenesis, autophagy research, and PI3K-Akt-Foxo1 signaling. This article translates its product characteristics and the KDM4D-MSC study into practical assay workflows, controls, and troubleshooting decisions.
-
Grazoprevir Hydrate: From Protease to Patient Data
2026-08-27
Grazoprevir hydrate is an exceptionally potent HCV NS3/4A protease inhibitor, but its value is best understood through a translational framework linking enzyme assays, genotype-specific replication models, pharmacokinetics, and clinical outcomes.
-
Merimepodib (VX-497) in IMPDH Workflows
2026-08-27
Merimepodib (VX-497) is a practical probe for testing whether guanine nucleotide supply limits lymphocyte growth or viral replication. This workflow translates PEDV host-dependency findings into controlled antiviral, immunology, and oncology assays with rescue controls, orthogonal readouts, and troubleshooting guidance.
-
TRIM21, ERK1/2, and Drug Resistance in Pituitary Adenomas
2026-08-26
The reference study identifies TRIM21 as an E3 ligase that promotes ERK1/2 ubiquitination, phosphorylation, pituitary adenoma cell proliferation, and dopamine-agonist resistance. Its combination of CRISPR screening, biochemical validation, animal studies, and NanoBiT-based drug screening highlights TRIM21 as a mechanistically supported target while positioning Quisinostat as a candidate for further investigation.
-
ECL Western Blotting Substrate: Practical Guide
2026-08-26
ECL Western Blotting Substrate (SKU K2187) is a luminol-based horseradish peroxidase detection reagent for sensitive, nonradioactive protein detection by chemiluminescence. It is intended for HRP-based Western blot workflows using X-ray film or CCD imaging, not for fluorescent or radioisotopic detection.